GLP-1 weight loss drugs are producing the kind of adverse event data that is starting to break through to mainstream audiences, and the warning signs are coming from credible sources.

Harvard medical researcher Dr. David Sinclair told Joe Rogan that sudden blindness has doubled since the rollout of GLP-1 drugs, caused by a condition called NAION, a stroke-like event in the eye for which there is no treatment. Actress and neuroscientist Mayim Bialik disclosed her own severe experience publicly, including dehydration bad enough to require IV treatment at home. UK regulatory data shows 216 deaths and 18,000 severe reactions linked to GLP-1 drugs, with annual fatalities rising 300% between 2024 and 2025. The FDA's adverse event reporting system shows 228,350 total reported cases, 60,762 serious cases including deaths, and 1,631 deaths. A class action lawsuit over stomach paralysis is seeking $2 billion from Ozempic's manufacturer. A STAT News investigation into Life.MD, a major telehealth platform, found providers were expected to review 25 patient cases per hour based only on electronic forms, approximately two minutes per case, and were discouraged from asking medically relevant questions that might slow throughput.

However, there is a distinction between this conversation and the COVID vaccine mandate situation: GLP-1s are an adult choice driven by real medical risks of obesity, and microdosing approaches supervised by qualified practitioners appear to produce very different outcomes than the self-administered or high-dose telehealth model. The concern is whether patients are being properly informed of the risks and properly supervised during treatment.

@delbigtree